First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M(1)‐receptor partial agonist for the treatment of dementias

AIMS: HTL0018318 is a selective M(1) receptor partial agonist currently under development for the symptomatic treatment of cognitive and behavioural symptoms in Alzheimer's disease and other dementias. We investigated safety, tolerability, pharmacokinetics and exploratory pharmacodynamics (PD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakker, Charlotte, Tasker, Tim, Liptrot, Jan, Hart, Ellen P., Klaassen, Erica S., Prins, Samantha, van der Doef, Thalia F., Brown, Giles A., Brown, Alastair, Congreve, Miles, Weir, Malcolm, Marshall, Fiona H., Cross, David M., Groeneveld, Geert Jan, Nathan, Pradeep J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359307/
https://www.ncbi.nlm.nih.gov/pubmed/33351971
http://dx.doi.org/10.1111/bcp.14710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359307/
https://www.ncbi.nlm.nih.gov/pubmed/33351971
http://dx.doi.org/10.1111/bcp.14710

Ejemplares similares